全药物洗脱支架外套技术:Zilver PTX支架治疗股腘动脉长病变的单中心两年结果
回顾性分析89例股腘动脉闭塞性疾病患者,按病变长度分为短病变组(≤20 cm,n=41)和全药物洗脱支架外套组(>20 cm,n=48)。短病变组1年再狭窄率19% vs 长病变组40%(p=0.050),2年39% vs 54%(p=0.331);1年再干预率2% vs 21%(p=0.009),2年12% vs 33%(p=0.019)。作者认为Zilver PTX治疗>20 cm股腘动脉病变对症状性外周动脉疾病患者似乎是临床有效的疗法,但再狭窄和再干预需求持续增加至2年。
要点
- 短病变组1年再狭窄率19% vs 长病变组40%(p=0.050),2年39% vs 54%(p=0.331)。
- 短病变组1年再干预率2% vs 长病变组21%(p=0.009),2年12% vs 33%(p=0.019)。
- Zilver PTX治疗>20 cm股腘动脉病变似乎是临床有效的疗法,但再狭窄和再干预需求持续进展至2年。
核心结论
- Zilver PTX治疗>20 cm股腘动脉病变对症状性外周动脉疾病患者似乎是临床有效的疗法,但再狭窄和再干预需求持续增加至2年。
研究设计与样本
- 回顾性综述纳入89例连续患者(平均年龄68.7±9.8岁;86例男性),股腘动脉闭塞性疾病(Rutherford分级2-6级),于2012年12月至2013年12月接受Zilver PTX治疗。
- 全队列平均病变长度24.2±11.3 cm(中位数24.0,范围4-48 cm)。
- 患者分为短病变组(≤20 cm,n=41;平均病变长度13.3±5.6 cm)和全药物洗脱支架外套组(>20 cm,n=48;平均病变长度33.0±6.5 cm)。
- 主要终点为双功超声-derived再狭窄(收缩期峰值流速比>2.5)、临床驱动的再干预和重大截肢。
主要发现
- 短病变组1年再狭窄率19% vs 长病变组40%(p=0.050),2年39% vs 54%(p=0.331)。
- 短病变组1年再干预率2% vs 长病变组21%(p=0.009),2年12% vs 33%(p=0.019)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the 1- and 2-year patency and reintervention rates with the Zilver PTX drug-eluting stent (DES) in long complex femoropopliteal disease. METHODS: A retrospective review was conducted of 89 consecutive patients (mean age 68.7±9.8 years; 86 men) with femoropopliteal occlusive disease (Rutherford category 2-6) treated with the Zilver PTX between December 2012 and December 2013. Mean lesion length for the entire cohort was 24.2±11.3 cm (median 24.0, range 4-48). The patient population was dichotomized into a short lesion (≤20 cm) group (n=41; mean lesion length 13.3±5.6 cm) and the full DES jacket (>20 cm) group (n=48; mean lesion length 33.0±6.5 cm). Primary endpoints were duplex-derived restenosis (peak systolic velocity ratio >2.5), clinically driven reintervention, and major amputation. RESULTS: The incidence of restenosis was lower in the short lesion group at 1 year (19% vs 40% for the longer lesions, p=0.050) and 2 years (39% vs 54%, respectively; p=0.331). The short lesion group had significantly lower rates of reintervention at both 1 year (2% vs 21% in long lesions, p=0.009) and 2 years (12% vs 33%, p=0.019). CONCLUSION: Treatment of femoropopliteal lesions >20 cm with the Zilver PTX appears to be a clinically effective therapy for patients with symptomatic peripheral artery disease. However, there is an increase in restenosis and a need for reintervention that continues to progress up to 2 years.
引用
- Phillips JA, Falls A, Kolluri R, et al. Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries. J Endovasc Ther. 2018. PMID: 29544372. doi:10.1177/1526602818762805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。